Jane L. Meisel, MD

Articles

Dr Meisel on Perceptions of Patient/Provider Communication in Breast Cancer Care

March 1st 2024

Jane L. Meisel, MD, shares information from a study that evaluated patient-reported perceptions of patient-provider communication in breast cancer care.

Dr Meisel on Patient-Reported Perceptions of Provider Communication in Breast Cancer Care

February 20th 2024

Jane L. Meisel, MD, discusses patient-reported perceptions of patient-provider communication in cancer care.

Dr Meisel on Communication Barriers Between Patients and Oncologists in Breast Cancer

February 7th 2024

Jane L. Meisel, MD, discusses the rationale for evaluating communication challenges that currently exist between patients and their oncologists.

Dr Meisel on AE Communication Challenges in Metastatic Breast Cancer Treatment

January 11th 2024

Jane L. Meisel, MD, shares data from a study on communication challenges between providers and patients with metastatic breast cancer regarding TRAEs.

Novel Therapies Under Investigation for HER2+ mBC

November 3rd 2023

Jane Meisel, MD, shares enthusiasm about upcoming trials and therapies in HER2+ metastatic breast cancer, with new antibody-drug conjugates showing promise.

Monitoring Patients With HER2+ mBC After Discontinuing Trastuzumab Deruxtecan

November 3rd 2023

Jane Meisel, MD, delves into considerations around discontinuing trastuzumab deruxtecan for the treatment of HER2+ metastatic breast cancer, explaining that therapy may be halted due to disease progression or toxicity, and the importance of monitoring patients with regular scans.

Adverse Events Seen With Second- and Third-Line Therapies in Patients With HER2+ mBC

October 27th 2023

Jane Meisel, MD, discusses managing adverse events in patients receiving second- or third-line treatments for HER2+ metastatic breast cancer, emphasizing close monitoring, patient communication, and symptom-specific interventions.

Clinical Trial Data and Real-World Evidence on Therapy Sequencing for HER2+ mBC

October 27th 2023

Jane Meisel, MD, emphasizes the growing role of real-world evidence in guiding therapy sequencing for HER2+ metastatic breast cancer due to rapidly evolving treatment standards.

Approaches to Sequencing Therapies for HER2+ mBC

October 20th 2023

Jane Meisel, MD, describes a personalized approach to later lines of treatment for HER2+ metastatic breast cancer, explaining the importance of considering patient priorities and individual circumstances.

The Role of Trastuzumab Deruxtecan in the Treatment of HER2+ mBC

October 20th 2023

Jane Meisel, MD, elaborates on the evolution and significance of the antibody-drug conjugate trastuzumab deruxtecan in treating HER2+ metastatic breast cancer, highlighting its effectiveness and considerations for its usage.

Current Standard of Care for HER2+ Metastatic Breast Cancer (mBC)

October 13th 2023

Jane Meisel, MD, details the current standard-of-care for HER2+ metastatic breast cancer in the US, emphasizing personalized care and the importance of shared decision-making with patients.

Evolution of Advanced HER2+ Breast Cancer Management

October 13th 2023

Jane Meisel, MD, highlights how recent advancements in HER2+ advanced breast cancer treatments such as the introduction of tucatinib and trastuzumab deruxtecan are transforming patient care, particularly for those with brain metastases.

Dr. Meisel on Effect of the HER2-Low Classification Breast Cancer

January 4th 2023

Jane L. Meisel, MD, discusses the effect of the HER2-low classification for patients with breast cancer.

Dr. Meisel on Sequencing Therapies in Metastatic HER2+ Breast Cancer

April 21st 2021

Jane L. Meisel, MD, discusses sequencing therapies for patients with metastatic HER2-positive breast cancer.

Dr. Meisel the Potential Utility of CDK4/6 Inhibitors in HER2+ Breast Cancer

April 16th 2021

Jane L. Meisel, MD, discusses the potential utility of CDK4/6 inhibitors in HER2-positive metastatic breast cancer.

Dr. Meisel on Managing Toxicities Associated with T-DM1 in HER2+ Breast Cancer

April 6th 2021

Jane L. Meisel, MD, discusses managing toxicities associated with ado-trastuzumab emtansine in patients with HER2-positive breast cancer.

Dr. Meisel on the Nuances of Utilizing Adjuvant T-DM1 in HER2+ Breast Cancer

April 2nd 2021

Jane L. Meisel, MD, discusses some of the nuances of utilizing adjuvant ado-trastuzumab emtansine in HER2-positive breast cancer.

Dr. Meisel on Sequencing Considerations in First- and Second-Line HER2+ Breast Cancer

February 3rd 2021

Jane L. Meisel, MD, discusses sequencing considerations in the first- and second-line settings of HER2-positive breast cancer.

Dr. Meisel on Optimizing Genomic Assays in Early-Stage HR-Positive, HER2-Negative Breast Cancer

August 1st 2019

Jane L. Meisel, MD, an assistant professor, Department of Hematology and Medical Oncology and Department of Gynecology & Obstetrics, Winship Cancer Institute, Emory University School of Medicine, discusses optimizing genomic assays in early-stage hormone receptor (HR)–positive, HER2-negative breast cancer.

Dr. Meisel on Emerging Treatment Strategies in TNBC

February 27th 2019

Jane L. Meisel, MD, an assistant professor in the Department of Gynecology & Obstetrics at Emory School of Medicine, Winship Cancer Institute, discusses emerging treatment strategies in triple-negative breast cancer (TNBC).